

Europe Immunodiagnostics Market Forecast to 2030 - Regional Analysis - by Product (Enzyme-Linked Immunosorbent Assays (ELISA), Chemiluminescence Immunoassays (CLIA), Radioimmunoassays (RIA), and Others), By Clinical Indication (Infectious Diseases, Hepatitis+HIV, Endocrinology, Gastrointestinal, Metabolics, and Others), and End User (Hospitals, Clinics, Diagnostic Laboratories, Academic & Research Institutes, and Others)

Market Report | 2023-11-07 | 209 pages | The Insight Partners

AVAILABLE LICENSES:

- Single User Price \$3000.00
- Site Price \$4000.00
- Enterprise Price \$5000.00

Report description:

The Europe immunodiagnostics market is expected to grow from US\$ 6,131.85 million in 2023 to US\$ 10,098.03 million by 2030. It is estimated to grow at a CAGR of 7.4% from 2023 to 2030.

Increasing Prevalence of Infectious Diseases Drive Europe Immunodiagnostics Market

The diagnosis and management of several ever-growing infectious diseases caused by infectious agents such as viruses, fungi, bacteria, parasites, or their toxic products are surging number of prescriptions for immunodiagnostics tests, e.g., complement fixation, precipitation tests, agglutination tests, line blot assays, Western blot assays, enzyme immunoassays (EIA), and immunofluorescence tests. Human immunodeficiency virus (HIV) continues to be a major public health issue worldwide. Further, tuberculosis (TB), COVID-19, and other hospital-acquired infections (HAIs) require immunodiagnostics tests.

- TB has been the 13th leading cause of death and the second-leading infectious killer after COVID-19. In 2020, 1.5 million people died from TB and affected an estimated 10 million people, comprising 5.6 million males, 3.3 million females, and 1.1 million

children globally.

- According to Worldometer, millions of deaths were reported worldwide due to the COVID-19 pandemic. It strained healthcare systems and increased the need for immunodiagnostics tests.

Diagnostics play a vital role in determining suitable medical treatments. Immunodiagnostics help diagnose diseases that severely impact the immune system. Hence, the rising prevalence of infectious diseases lead to the surging demand for immunodiagnostics products.

Europe Immunodiagnostics Market Overview

The huge geriatric population is significantly driving the market for immunodiagnostics in Germany. According to the UN population data, 1 out of 20 Germans is aged above 80 years, and the number is expected to increase to 6 out of 20 by 2050. The risk of developing chronic diseases, such as cardiovascular diseases (CVDs), diabetes, and neurovascular disorders, increases with age. According to the estimates of the German Centre for Cancer Registry Data (ZfKD) published by the Robert Koch Institute in September 2023, in Germany, 502,655 people had cancer in 2019, among which 234,925 were women and 267,730 were men. It is estimated that the prevalence of cancer is likely to continue owing to lifestyle changes, obesity, unhealthy habits, and more. The most common cancers in Germany are breast, prostate, colorectum (large bowel), lung, and bladder cancer. These five cancer types accounted for about 57% of all new cancer diagnoses in Germany. Thus, the increasing prevalence of cancer is likely to propel the demand for immunodiagnostics.

Germany is the leading medical biotech nation in the world after the US. In 2020, the German biotechnology sector grew significantly compared to the pre-COVID year 2018. The positive market trend has accelerated in the last few years in some areas; and according to the OECD-compliant survey by BIOCOM, the German biotechnology industry's turnover increased by almost 50% in 2020. The presence of long-established companies and the emergence of start-ups affirmed the industrial strength. Industry, government, and research sectors thrive on strong market foundations. With many European biotech companies, world-class research infrastructure, and internationally renowned scientists, Germany has firmly established itself as an international medical biotechnology hub. German biotech companies emerged as global leaders in mRNA technologies by introducing the first COVID-19 test and vaccination, approved by the European Medicines Agency. Such developments have encouraged enhanced technological advancements for immunodiagnostics. Thus, the rising biotechnology sector will likely boost the country's immunodiagnostics market.

Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US\$ Million)

Europe Immunodiagnostics Market Segmentation

The Europe immunodiagnostics market is segmented into product, clinical indication, end user, and country.

Based on product, the Europe immunodiagnostics market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others. In 2023, the enzyme-linked immunosorbent assays (ELISA) segment registered the largest share in the Europe immunodiagnostics market. The chemiluminescence immunoassays (CLIA) segment is further segmented into vitamin D assay market, HIV detection market, HIV ag/ab combo assay market, and other tests.

Based on clinical indication, the Europe immunodiagnostics market is segmented into infectious diseases, hepatitis+hiv, endocrinology, gastrointestinal, metabolics, and others. In 2023, the infectious diseases segment registered the largest share in the Europe immunodiagnostics market. The infectious diseases segment is further segmented into COVID-19, tuberculosis, lyme, infection management, zika, treponema, torch, measles and mumps, VZV, and EBV. The endocrinology segment is further segmented into hypertension, growth, diabetes, thyroid, and reproductive endocrinology.

Based on end user, the Europe immunodiagnostics market is segmented into hospitals, clinics, diagnostic laboratories, academic & research institutes, and others. In 2023, the hospitals segment registered the largest share in the Europe immunodiagnostics market.

Based on country, the Europe immunodiagnostics market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. In 2023, Germany segment registered the largest share in the Europe immunodiagnostics market.

Abbott Laboratories; bioMerieux SA; Danaher Corp; DiaSorin SpA; F. Hoffmann-La Roche Ltd; PerkinElmer Inc; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthcare GmbH; Svar Life Science AB; and Thermo Fisher Scientific Inc are some of the leading companies operating in the Europe immunodiagnostics market.

Table of Contents:

TABLE OF CONTENTS

1. Introduction 1.1 Scope of the Study 1.2 The Insight Partners Research Report Guidance 1.3 Market Segmentation 1.3.1 Europe Immunodiagnostics Market - by Product 1.3.2 Europe Immunodiagnostics Market - by Clinical Indication 1.3.3 Europe Immunodiagnostics Market - by End User 1.3.4 Europe Immunodiagnostics Market - by Country 2. Europe Immunodiagnostics Market - Key Takeaways 3. Research Methodology 3.1 Coverage 3.2 Secondary Research 3.3 Primary Research 4. Europe Immunodiagnostics Market - Market Landscape 4.1 Overview 4.2 Europe PEST Analysis 4.3 Expert's Opinion 5. Europe Immunodiagnostics Market - Key Market Dynamics 5.1 Market Drivers 5.1.1 Increasing Prevalence of Infectious Diseases 5.1.2 Growing Use of Point-of-Care Immunodiagnostics 5.2 Market Restraints 5.2.1 Inadequate Reimbursement Scenario 5.3 Market Opportunities 5.3.1 Rising Focus on R&D Investment and Expansion by Key Players 5.4 Future Trends 5.4.1 Technological Advancements in Immunodiagnostics 5.5 Impact Analysis 6. Immunodiagnostics Market - Europe Analysis 6.1 Europe Immunodiagnostics Market Revenue Forecast and Analysis 7. Europe Immunodiagnostics Market Analysis - by Product 7.1 Overview

7.2 Europe Immunodiagnostics Market, By Product, 2022 & 2030 (%) 7.3 Enzyme-linked Immunosorbent Assays (ELISA) 7.3.1 Overview 7.3.2 Enzyme-linked Immunosorbent Assays (ELISA): Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US\$ Million) 7.4 Chemiluminescence Immunoassays (CLIA) 7.4.1 Overview 7.4.2 Chemiluminescence Immunoassays (CLIA): Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US\$ Million) 7.4.3 Vitamin D Assay 7.4.3.1 Overview 7.4.3.2 Vitamin D Assay: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US\$ Million) 7.4.4 HIV Detection 7.4.4.1 Overview 7.4.4.2 HIV Detection: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US\$ Million) 7.4.5 HIV Ag/Ab Combo assay 7.4.5.1 Overview 7.4.5.2 HIV Ag/Ab Combo Assay: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US\$ Million) 7.4.6 Other Tests 7.4.6.1 Overview 7.4.6.2 Other Tests: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US\$ Million) 7.5 Radioimmunoassays (RIA) 7.5.1 Overview 7.5.2 Radioimmunoassays (RIA): Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US\$ Million) 7.6 Others 7.6.1 Overview 7.6.2 Others: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US\$ Million) 8. Europe Immunodiagnostics Market Analysis - Clinical Indication 8.1 Overview 8.2 Europe Immunodiagnostics Market Share by Clinical Indication - 2022 & 2030 (%) 8.3 Infectious Diseases: 8.3.1 Overview 8.3.2 Infectious Diseases: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US\$ Million) 8.3.2.1 COVID-19 8.3.2.1.1 Overview 8.3.2.1.2 COVID-19: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US\$ Million) 8.3.2.2 Tuberculosis 8.3.2.2.1 Overview 8.3.2.2.2 Tuberculosis: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US\$ Million) 8.3.2.3 Lyme 8.3.2.3.1 Overview 8.3.2.3.2 Lyme: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US\$ Million) 8.3.2.4 Infection Management 8.3.2.4.1 Overview 8.3.2.4.2 Infection Management: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US\$ Million) 8.3.2.5 Zika 8.3.2.5.1 Overview 8.3.2.5.2 Zika: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US\$ Million)

8.3.2.6 Treponema	
8.3.2.6.1 Overview	
8.3.2.6.2 Treponema: Europe Immunodiagnostics Market Revenue and	Forecast to 2030 (US\$ Million)
8.3.2.7 TORCH	
8.3.2.7.1 Overview	
8.3.2.7.2 TORCH: Europe Immunodiagnostics Market Revenue and Fore	ecast to 2030 (US\$ Million)
8.3.2.8 Measles and Mumps	
8.3.2.8.1 Overview	
8.3.2.8.2 Measles and Mumps: Europe Immunodiagnostics Market Reve	enue and Forecast to 2030 (US\$ Million)
8.3.2.9 VZV	
8.3.2.9.1 Overview	
8.3.2.9.2 VZV: Europe Immunodiagnostics Market Revenue and Foreca	st to 2030 (US\$ Million)
8.3.2.10 EBV	
8.3.2.10.1 Overview	
8.3.2.10.2 EBV: Europe Immunodiagnostics Market Revenue and Foreca	ast to 2030 (US\$ Million)
8.4 Hepatitis+HIV:	
8.4.1 Overview	
8.4.2 Hepatitis+HIV: Europe Immunodiagnostics Market Revenue and F	orecast to 2030 (US\$ Million)
8.5 Gastrointestinal	
8.5.1 Overview	
8.5.2 Gastrointestinal: Europe Immunodiagnostics Market Revenue and	l Forecast to 2030 (US\$ Million)
8.6 Metabolic Disorders	
8.6.1 Overview	
8.6.2 Metabolics: Europe Immunodiagnostics Market Revenue and Fore	cast to 2030 (US\$ Million)
8.7 Endocrinology	
8.7.1 Overview	
8.7.2 Endocrinology: Europe Immunodiagnostics Market Revenue and F	orecast to 2030 (US\$ Million)
8.7.3 Hypertension	
8.7.3.1 Overview	Encount to 2020 (USt Million)
8.7.3.2 Hypertension: Europe Immunodiagnostics Market Revenue and 8.7.4 Growth	
8.7.4.1 Overview	
8.7.4.2 Growth: Europe Immunodiagnostics Market Revenue and Forec	ast to 2020 (US¢ Million)
8.7.5 Diabetes	
8.7.5.1 Overview	
8.7.5.2 Diabetes: Europe Immunodiagnostics Market Revenue and Fore	ecast to 2030 (LIS\$ Million)
8.7.6 Thyroid	
8.7.6.1 Overview	
8.7.6.2 Thyroid: Europe Immunodiagnostics Market Revenue and Forec	ast to 2030 (US\$ Million)
8.7.7 Reproductive Endocrinology	
8.7.7.1 Overview	
8.7.7.2 Reproductive Endocrinology: Europe Immunodiagnostics Marke	t Revenue and Forecast to 2030 (US\$ Million)
8.8 Others	
8.8.1 Overview	
8.8.2 Others: Europe Immunodiagnostics Market Revenue and Forecast	to 2030 (US\$ Million)
9. Europe Immunodiagnostics Market Analysis - End User	
9.1 Overview	

9.2 Europe Immunodiagnostics Market Share by End User - 2022 & 2030 (%)

9.3 Hospitals

9.3.1 Overview

9.3.2 Hospitals: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US\$ Million)

9.4 Clinics

9.4.1 Overview

9.4.2 Clinics: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US\$ Million)

9.5 Diagnostic Laboratories

9.5.1 Overview

9.5.2 Diagnostic Laboratories: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US\$ Million)

9.6 Academic and Research Institutes

9.6.1 Overview

9.6.2 Academic and Research Institutes: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US\$ Million)

9.7 Others

9.7.1 Overview

9.7.2 Others: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US\$ Million)

10. Europe Immunodiagnostics Market - Revenue and Forecast to 2030 - Country Analysis

10.1 Overview

10.1.1.1 UK: Immunodiagnostics Market - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.1.1 Overview

10.1.1.1.2 UK: Immunodiagnostics Market - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.1.3 UK: Immunodiagnostics Market, by Product, 2020-2030 (US\$ Million)

10.1.1.1.3.1 UK: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)

10.1.1.1.4 UK: Immunodiagnostics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.1.4.1 UK: Immunodiagnostics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.1.4.2 UK: Immunodiagnostics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.1.5 UK: Immunodiagnostics Market, by End User, 2020-2030 (US\$ Million)

10.1.1.2 Germany: Immunodiagnostics Market - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.2.1 Overview

10.1.1.2.2 Germany: Immunodiagnostics Market - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.2.3 Germany: Immunodiagnostics Market, by Product, 2020-2030 (US\$ Million)

10.1.1.2.3.1 Germany: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)

10.1.1.2.4 Germany: Immunodiagnostics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.2.4.1 Germany: Immunodiagnostics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.2.4.2 Germany: Immunodiagnostics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.2.5 Germany: Immunodiagnostics Market, by End User, 2020-2030 (US\$ Million)

10.1.1.3 France: Immunodiagnostics Market - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.3.1 Overview

10.1.1.3.2 France: Immunodiagnostics Market - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.3.3 France: Immunodiagnostics Market, by Product, 2020-2030 (US\$ Million)

10.1.1.3.3.1 France: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)

10.1.1.3.4 France: Immunodiagnostics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.3.4.1 France: Immunodiagnostics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.3.4.2 France: Immunodiagnostics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.1.1.3.5 France: Immunodiagnostics Market, by End User, 2020-2030 (US\$ Million)

10.1.1.4 Italy: Immunodiagnostics Market - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.4.1 Overview

10.1.1.4.2 Italy: Immunodiagnostics Market - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.4.3 Italy: Immunodiagnostics Market, by Product, 2020-2030 (US\$ Million)

10.1.1.4.3.1 Italy: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)

10.1.1.4.4 Italy: Immunodiagnostics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.4.4.1 Italy: Immunodiagnostics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.4.4.2 Italy: Immunodiagnostics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.4.5 Italy: Immunodiagnostics Market, by End User, 2020-2030 (US\$ Million)

10.1.1.5 Spain: Immunodiagnostics Market - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.5.1 Overview

10.1.1.5.2 Spain: Immunodiagnostics Market - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.5.3 Spain: Immunodiagnostics Market, by Product, 2020-2030 (US\$ Million)

10.1.1.5.3.1 Spain: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)

10.1.1.5.4 Spain: Immunodiagnostics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.5.4.1 Spain: Immunodiagnostics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.5.4.2 Spain: Immunodiagnostics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.5.5 Spain: Immunodiagnostics Market, by End User, 2020-2030 (US\$ Million)

10.1.1.6 Rest of Europe: Immunodiagnostics Market - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.6.1 Overview

10.1.1.6.2 Rest of Europe: Immunodiagnostics Market - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.6.3 Rest of Europe: Immunodiagnostics Market, by Product, 2020-2030 (US\$ Million)

10.1.1.6.3.1 Rest of Europe: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US\$ Million)

10.1.1.6.4 Rest of Europe: Immunodiagnostics Market, by Clinical Indication - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.6.4.1 Rest of Europe: Immunodiagnostics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.6.4.2 Rest of Europe: Immunodiagnostics Market, by Endocrinology - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.6.5 Rest of Europe: Immunodiagnostics Market, by End User, 2020-2030 (US\$ Million)

11. Europe Immunodiagnostics Market -Industry Landscape

11.1 Overview

11.2 Inorganic Growth Strategies

11.2.1 Overview

11.3 Organic Growth Strategies

11.3.1 Overview

12. Company Profiles

12.1 Abbott Laboratories

12.1.1 Key Facts

12.1.2 Business Description

12.1.3 Products and Services

12.1.4 Financial Overview

12.1.5 SWOT Analysis

12.1.6 Key Developments

12.2 F. Hoffmann-La Roche Ltd

12.2.1 Key Facts

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com

12.2.2 Business Description 12.2.3 Products and Services 12.2.4 Financial Overview 12.2.5 SWOT Analysis 12.2.6 Key Developments 12.3 DiaSorin SpA 12.3.1 Key Facts 12.3.2 Business Description 12.3.3 Products and Services 12.3.4 Financial Overview 12.3.5 SWOT Analysis 12.3.6 Key Developments 12.4 Danaher Corp 12.4.1 Key Facts 12.4.2 Business Description 12.4.3 Products and Services 12.4.4 Financial Overview 12.4.5 SWOT Analysis 12.4.6 Key Developments 12.5 Thermo Fisher Scientific Inc 12.5.1 Key Facts 12.5.2 Business Description 12.5.3 Products and Services 12.5.4 Financial Overview 12.5.5 SWOT Analysis 12.5.6 Key Developments 12.6 PerkinElmer Inc 12.6.1 Key Facts 12.6.2 Business Description 12.6.3 Products and Services 12.6.4 Financial Overview 12.6.5 SWOT Analysis 12.6.6 Key Developments 12.7 Shenzhen Mindray Bio-Medical Electronics Co., Ltd. 12.7.1 Key Facts 12.7.2 Business Description 12.7.3 Products and Services 12.7.4 Financial Overview 12.7.5 SWOT Analysis 12.7.6 Key Developments 12.8 bioMerieux SA 12.8.1 Key Facts 12.8.2 Business Description 12.8.3 Products and Services 12.8.4 Financial Overview 12.8.5 SWOT Analysis 12.8.6 Key Developments

12.9 Svar Life Science AB 12.9.1 Key Facts 12.9.2 Business Description 12.9.3 Products and Services 12.9.4 Financial Overview 12.9.5 SWOT Analysis 12.9.6 Key Developments 12.10 Siemens Healthcare GmbH 12.10.1 Key Facts 12.10.2 Business Description 12.10.3 Products and Services 12.10.4 Financial Overview 12.10.5 SWOT Analysis 12.10.6 Key Developments 13. Appendix 13.1 About The Insight Partners 13.2 Glossary of Terms



Europe Immunodiagnostics Market Forecast to 2030 - Regional Analysis - by Product (Enzyme-Linked Immunosorbent Assays (ELISA), Chemiluminescence Immunoassays (CLIA), Radioimmunoassays (RIA), and Others), By Clinical Indication (Infectious Diseases, Hepatitis+HIV, Endocrinology, Gastrointestinal, Metabolics, and Others), and End User (Hospitals, Clinics, Diagnostic Laboratories, Academic & Research Institutes, and Others)

Market Report | 2023-11-07 | 209 pages | The Insight Partners

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User Price	\$3000.00
	Site Price	\$4000.00
	Enterprise Price	\$5000.00
	VAT	
	Total	

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346. []** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	Phone*	
First Name*	Last Name*	
Job title*		

Company Name*	EU Vat / Tax ID / NIP number*	
Address*	City*	
Zip Code*	Country*	
	Date	2025-06-23
	Signature	